Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
Bristol Myers drug delays myeloma progression in hard to treat patients
08:02am, Friday, 29'th May 2026
Bristol Myers Squibb said on Friday that its experimental oral drug mezigdomide delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed or not resp
How Bristol Is Building On Its $74 Billion Celgene Buyout With New 'Molecular Glue'
08:00am, Friday, 29'th May 2026
Bristol Myers Squibb said Friday its drug, mezigdomide, lowered the risk of progression or death for multiple myeloma patients by over half.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in.
Bristol-Myers Squibb Is Quietly Building Its Next Growth Cycle
10:09am, Wednesday, 27'th May 2026
Bristol-Myers Squibb Company sees its business tracking toward the upper end of full-year 2026 revenue and EPS guidance ranges. In my view, this primarily reflects strong demand for Breyanzi, Camzyos,
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
06:59am, Wednesday, 27'th May 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference.
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
10:40am, Tuesday, 26'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Looking to Buy Bristol Myers Squibb Stock on the Dip? Read This First.
05:50am, Sunday, 24'th May 2026
Bristol Myers Squibb faces a daunting patent cliff. The company has a promising growth portfolio, but it may not be able to fully offset losses from older drugs.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Unveil New Data at ASCO 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline.
The Most Undervalued Healthcare Stock in the S&P 500 Right Now
07:05am, Thursday, 21'st May 2026
The market appears to be short-sighted.
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery
07:49am, Wednesday, 20'th May 2026
Bristol Myers Squibb said on Wednesday it is partnering with Anthropic to make its Claude AI model available to over 30,000 employees in an effort to accelerate the discovery, development and de
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across.
Bristol-Myers Squibb Brings Anthropic's Claude to 30,000 of Its Staff
06:45am, Wednesday, 20'th May 2026
The deal helps solidify Anthropic's commitment to the life sciences sector as it targets more enterprise clients.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Tuesday, 19'th May 2026
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
08:24am, Tuesday, 19'th May 2026
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high
3 High-Yielding Dividend Stocks Trading at Dirt Cheap Valuations
02:00pm, Monday, 18'th May 2026
The stocks listed here yield between 3.8% and 7.4%. Their valuations are incredibly low when compared to the S&P 500.
